Quantcast

Rottenstein Law Group Shares Concern That Osteoporosis Is Undertreated, But Prescribes Prudence Regarding Bisphosphonate Drugs

November 7, 2011

The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, is concerned that many with osteoporosis might not know it and therefore might not be getting necessary treatment timely, but maintains that those who are diagnosed with the condition should discuss with their physicians in detail the possible serious adverse side effects of bisphosphonate drugs.

New York, NY (PRWEB) November 07, 2011

According to an October 31, 2011, New York Times article, âœOsteoporosis is both underdiagnosed and undertreated. Doctors say it is underdiagnosed because many who have it fail to get a bone density test, sometimes even after they suffer a fracture. The condition is undertreated because some people avoid drug therapy for fear of side effects, while others take their medications erratically or stop taking them altogether without consulting their doctors.â

The Times piece notes: âœSome 10 million Americans have osteoporosis, and 34 million more with low bone mass are at risk of developing it. It is a silent disease that typically first shows up as a low-trauma fracture of the hip, spine or wrist. Low-trauma does not mean no trauma; someone with healthy bones who falls from a standing height or less is unlikely to break a bone, according to Dr. Sundeep Khosla, president of the American Society for Bone and Mineral Research.â

âœWhen drugs called bisphosphonates were introduced to prevent and treat osteoporosis (Fosamax, now available as a generic called alendronate, was the first),â Times writer Jane E. Brody submits, âœoverly enthusiastic doctors prescribed them for millions of postmenopausal women who were not at high risk of fracture.â But a recently published study âœexamined the use of bisphosphonates among 12,777 Swedish women age 55 or older who suffered a fracture of the femur in 2008. Although those who had taken the drugs were 47 times as likely as those who had not to have experienced an atypical femur fracture, the actual number of these fractures was only 5 in 2,000 women who had used the drugs for five years.â

Nevertheless, two advisory panels of the U.S. Food and Drug Administration recently recommended that labels of bisphosphonate drugs should be changed to reflect uncertainty about the risks and benefits of long-term use. The FDA had asked two of its advisory panels to recommend whether a âœdrug holidayâ or some time limit was warranted on the class of osteoporosis drugs known as bisphosphonates, which have been linked to unusual thigh fractures and other side effects.

The Rottenstein Law Group urges anyone whose friend or relative has been prescribed Fosamax or another osteoporosis drug to reach out to that person and recommend that he or she consult a physician immediately and then speak to a qualified personal injury lawyer. The Rottenstein Law Group maintains a Fosamax Lawsuit Information Center at http://www.fosamaxfemurfracturelawsuit.com. The site has features that allow for easy sharing, including links for automatic posting on Facebook and Twitter, specifically to enable visitors to spread the word about the dangers of Fosamax.

About THE ROTTENSTEIN LAW GROUP

The Rottenstein Law Group is a New York-based law firm that represents clients in dangerous drug lawsuits. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective consumer products. http://www.rotlaw.com


Contact:

The Rottenstein Law Group LLP

Rochelle Rottenstein, Esq.

1259 Veeder Drive

Hewlett NY 11557

(212) 933-9500 (office phone)

(212) 933-9980 (facsimile)

rochelle(at)rotlaw(dot)com

http://www.rotlaw.com

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/11/prweb8934963.htm


Source: prweb



comments powered by Disqus